Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
Lillehei Heart Institute, Department of Pediatrics, University of Minnesota, Minneapolis, United States.
Curr Stem Cell Res Ther. 2019;14(4):320-326. doi: 10.2174/1574888X14666190103170109.
Mesenchymal stem cells (MSCs) are multipotent stem cells with wide-ranging clinical applications due to their ability to regenerate tissue from mesenchymal origin and their capability of suppressing immune responses, thus reducing the likelihood of graft versus host disease after transplantation. MSCs can be isolated from a variety of sources including bone marrow, adipose tissue, umbilical cord blood, and immature teeth. Dental stem cells (DSCs) possess progenitor and immunomodulatory abilities as the other MSC types and because they can be easily isolated, are considered as attractive therapeutic agents in regenerative dentistry. Recently, it has been shown that DSCs seeded onto newly developed synthetic biomaterial scaffolds have retained their potential for proliferation and at the same time have enhanced capabilities for differentiation and immunosuppression. The scaffolds are becoming more efficient at MSC priming as researchers learn how short peptide sequences alter the adhesive and proliferative capabilities of the scaffolds by stimulating or inhibiting classical osteogenic pathways. New findings on how to modulate the inflammatory microenvironment, which can prime DSCs for differentiation, combined with the use of next generation scaffolds may significantly improve their therapeutic potential. In this review, we summarize current findings regarding DSCs as a potential regenerative therapy, including stem cell priming with inflammatory cytokines, types of scaffolds currently being explored and the modulation of scaffolds to regulate immune response and promote growth.
间充质干细胞(MSCs)是多能干细胞,由于其能够从间充质来源再生组织,以及能够抑制免疫反应,从而降低移植后移植物抗宿主病的可能性,因此具有广泛的临床应用。MSCs 可以从多种来源分离,包括骨髓、脂肪组织、脐带血和未成熟牙齿。与其他 MSC 类型一样,牙髓干细胞(DSCs)具有祖细胞和免疫调节能力,并且由于它们易于分离,因此被认为是再生牙科治疗中有吸引力的治疗剂。最近,已经表明,在新开发的合成生物材料支架上播种 DSCs 后,它们保持了增殖的潜力,同时增强了分化和免疫抑制的能力。随着研究人员了解短肽序列如何通过刺激或抑制经典成骨途径来改变支架的粘附和增殖能力,支架在 MSC 启动方面变得更加有效。关于如何调节炎症微环境的新发现可以为 DSCs 的分化做好准备,结合使用下一代支架可能会显著提高其治疗潜力。在这篇综述中,我们总结了 DSCs 作为一种潜在的再生治疗方法的最新发现,包括用炎症细胞因子启动干细胞、目前正在探索的支架类型以及调节支架以调节免疫反应和促进生长。